

EMA/71511/2021

European Medicines Agency decision P/0073/2021

of 17 March 2021

on the acceptance of a modification of an agreed paediatric investigation plan for doravirine/islatravir (EMA-002707-PIP01-19-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0073/2021

of 17 March 2021

on the acceptance of a modification of an agreed paediatric investigation plan for doravirine/islatravir (EMA-002707-PIP01-19-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0395/2020 issued on 23 October 2020,

Having regard to the application submitted by Merck Sharp & Dohme (Europe), Inc. on 26 October 2020 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 29 January 2021, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for doravirine/islatravir, tablet, age-appropriate oral solid dosage form, oral use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Merck Sharp & Dohme (Europe), Inc., 5 Clos du Lynx / Lynx Binnenhof 5, B-1200 - Brussels, Belgium.

EMA/PDCO/589233/2020
Amsterdam, 29 January 2021

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-002707-PIP01-19-M01

Scope of the application

Active substance(s):

Doravirine/islatravir

Condition(s):

Treatment of human immunodeficiency virus-1 (HIV-1) infection

Pharmaceutical form(s):

Tablet

Age-appropriate oral solid dosage form

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Merck Sharp & Dohme (Europe), Inc.

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Merck Sharp & Dohme (Europe), Inc. submitted to the European Medicines Agency on 26 October 2020 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0395/2020 issued on 23 October 2020.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 1 December 2020.

Scope of the modification

Some measures of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of human immunodeficiency virus-1 (HIV-1) infection

The waiver applies to:

- the paediatric population from birth to less than 28 days of age;
- tablet, age-appropriate oral solid dosage form, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric investigation plan

2.1. Condition:

Treatment of human immunodeficiency virus-1 (HIV-1) infection

2.1.1. Indication(s) targeted by the PIP

Treatment of human immunodeficiency virus-1 (HIV-1) infection

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 28 days to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Tablet

Age-appropriate oral solid dosage form

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	Study 1 Development of an age appropriate oral solid dosage form.
Non-clinical studies	0	Not applicable.
Clinical studies	2	Study 2 Open label uncontrolled study to evaluate islatravir (MK-8591) pharmacokinetic and the safety and activity of doravirine (DOR)/islatravir (ISL) in paediatric participants who are less than 18 years of age and weigh ≥ 35 kg with HIV-1 infection (P028).

Area	Number of measures	Description
		Study 3 Open label uncontrolled pharmacokinetic safety and activity study of the fix-doe combination (FDC) of doravirin/ islatravir (age appropriate formulation) for paediatric subjects who are at least 28 days of age and weigh less than 35kg.
Extrapolation, modelling and simulation studies	2	Study 4 Modelling and simulation study to support ISL dose finding in paediatric subjects weighing at least 35 kg. Study 5 Modelling and simulation study to support ISL dose finding in paediatric subjects at least 28 days of age and weighing less than 35 kg.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By March 2028
Deferral for one or more measures contained in the paediatric investigation plan:	Yes